Table 4. Comparison of clinical, laboratorial and radiological features between controlled (normal IGF-I levels on pegvisomant (PEGV-ON) and uncontrolled acromegaly patients.
| Controlled (N = 80) | Not controlled (N = 29) | P-value | |
|---|---|---|---|
| Age at diagnosis (yrs) | 35 (12 – 75) | 31 (12 – 82) | 0.09 |
| Female (%) | 44 (55) | 17 (58.6) | 0.73 |
| Tumour Remnant (%) | 55 (68.7) | 22 (78.6) | 0.32 |
| Previous radiotherapy (%) | 26 (32.5) | 11 (37.9) | 0.59 |
| Pre-Diabetes/Diabetes (%) | 36 (45) | 17 (58.6) | 0.20 |
| PEGV exposure (months) | 41 (2 – 120) | 22 (3 – 124) | 0.03 |
| GH PEGV-OFF (µg/L) | 3.75 (0.71 – 101) | 7.80 (1.03 – 209) | 0.01 |
| IGF-I PEGV-OFF (ng/mL) | 570 (262 – 1155) | 717 (279 – 1503) | < 0.001 |
| IGF-I PEGV-OFF (ULN%) | 194 (99 – 434) | 241 (124 – 637) | < 0.001 |
PEGV-OFF: just before PEGV treatment; %ULN: % upper limit of normal.